Log in to search using one of your social media accounts:

 

Corynebacterium, Kingella Abundance Tied to HNSCC Risk

No correlation for overall microbiome composition with risk of head and neck squamous cell carcinoma
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, ENT, Pathology, Journal, Source Type: news

Related Links:

Authors: Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J Abstract The standard first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma combines Cisplatin, 5 Fluorouracil and Cetuximab, but many patients aren't eligible. We retrospectively evaluated the efficacy and the tolerability of Carboplatin and Paclitaxel in this indication, mostly in patients unfit to Cisplatin. Paclitaxel (80mg/m2) was administered at day 1, 8 and 15 and Carboplatin area under the curve 5 at day 1, repeated every 28 days, for 6 cycles. Carboplatin could be...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion: In our study the overlap between baseline and post-therapeutic metabolic tumor sub-volumes was only moderate. These results need to be investigated in a larger cohort acquired with a more standardized patient repositioning protocol for sequential PET imaging. Methods: Pre and post treatment PET/CT scans of ninety four HNSCC patients treated with radio-chemotherapy were retrospectively reviewed. Follow-up 18F-FDG PET/CT images were registered to baseline scans using a rigid body transformation. Seven metabolic tumor sub-volumes were obtained on the baseline scans using a fixed percentage of SUVmax (I30, I40,...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Surov A, Meyer HJ, Leifels L, Höhn AK, Richter C, Winter K Abstract Our purpose was to analyze possible associations between histogram analysis parameters of dynamic contrast-enhanced magnetic resonance imaging DCE MRI and histopathological findings like proliferation index, cell count and nucleic areas in head and neck squamous cell carcinoma (HNSCC). 30 patients (mean age 57.0 years) with primary HNSCC were included in the study. In every case, histogram analysis parameters of Ktrans, Ve, and Kep were estimated using a mathlab based software. Tumor proliferation index, cell count, and nucleic areas ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
C, Hjuler T PMID: 29775116 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
The objective of this randomized trial was to compare two methods of re-irradiation in terms of toxicity and survival.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original article Source Type: research
Gunnar Wichmann, Claudia Lehmann, Cindy Herchenhahn, Marlen Kolb, Mathias Hofer, Susanne Wiegand, Andreas Dietz
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: SOX2 dampens the immunogenicity of HNSCC by targeting the STING pathway for degradation. The nanosatellite vaccine offers a novel and effective approach to enhance the adjuvant potential of STING agonist and break cancer tolerance to immunotherapy. PMID: 29769207 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conditions:   Head and Neck Squamous Cell Carcinoma;   Cutaneous Squamous Cell Carcinoma;   Head and Neck Cancer;   Head and Neck Carcinoma Interventions:   Drug: Lenvatinib Pill;   Drug: Cetuximab Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
hild SI Abstract Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from multiple anatomical subsites in the head and neck region. The treatment for early-stage disease is generally single modality, either surgery or radiotherapy. The treatment for locally advanced tumours is multimodal. For recurrent/metastatic HNSCC palliative chemotherapy is standard of care. The prognosis is limited and novel treatment approaches are urgently needed. HNSCC evades immune responses through multiple resistance mechanisms. HNSCC is particularly characterised by an immunosuppressive environment which include...
Source: Swiss Medical Weekly - Category: General Medicine Authors: Tags: Swiss Med Wkly Source Type: research
ConclusionThe combination of HPV status and prognostic copy number alteration detected by FISH in biopsies or cytological specimens may be an applicable protocol for screening head and neck cancer patients prior to therapy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | HNSCC | Pathology | Skin Cancer | Squamous Cell Carcinoma